More than 200 participants enrolled as company targets topline data by end of 2026 More: Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101 Source: News
read more
Oral therapy authorised for ER‑positive, HER2‑negative metastatic disease with ESR1 mutations More: MHRA approves imlunestrant tosylate as new breast cancer treatment Source: News
read moreAfter promising to sell off 7% of its business back in November, Charles River Laboratories has delivered. The CRO is offloading its entire contract manufacturing operation and some of its European discovery service assets, which brought in a combined $287
read moreIn developing media plans to reach the GLP-1-interested consumer, audio advertising may represent a “blind spot,” according to Anna Clement, director head of industry for SiriusXM Media’s pharma vertical. More: To reach consumers interested in GLP-1s, audio is ‘dramatically underutilized’:
read moreWhen BridgeBio presented its quarterly report on Tuesday, it laid out expectations on the potential threat of generic pricing pressure on Attruby and provided more evidence of the drug’s strong launch, possibly giving investors a dose of reassurance. More: As
read moreLearn about where, how, and when AI is actually making an impact on clinical development based on insights and experiences of working with pharma. More: How Evinova is Integrating AI into Clinical Development to Bring Big Impact to Big Pharma
read more© 1994 - 2026 B.M. Pharmaceuticals